Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. - Wikidata - awgldk - TriplyDB

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

http://www.wikidata.org/entity/Q36523502

about

Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.Molecular profiling of childhood cancer: Biomarkers and novel therapies Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.Pediatric CNS tumors: current treatment and future directions.Inheritance of susceptibility to induction of nephroblastomas in the Noble rat.New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Pediatric brain tumors: current treatment strategies and future therapeutic approaches Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.Met interacts with EGFR and Ron in canine osteosarcoma p53 family: Therapeutic targets in neuroblastoma.Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.Pediatric neuro-oncology: current status and future directions.Noscapine targets EGFR(p-Tyr1068) to suppress the proliferation and invasion of MG63 cells.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.Cross-talk between Notch and EGFR signaling in human breast cancer cells.

P2860

Q33730375-3B2E54B3-2FCD-4BF3-AC42-D0EA8CBF61EA Q33996096-61D5CAB0-BC94-4CAA-8123-C2F6A419C949 Q36250783-097E4D53-160E-474D-86DC-EE71D68DDEE1 Q36486421-59E0E0D6-0314-43BB-B054-505A1F8AD3E0 Q36803657-FB7A4AC6-546D-4601-AF06-FC26CB2D83C4 Q36902043-F2EF5B23-75A4-423E-9523-9BE4973CDE0D Q37226803-87BC6747-313C-4B51-B7D8-56DFBAF71130 Q37422646-697761BD-0180-42E9-BC16-CF0CA7C18A49 Q37533670-ED95F63C-E527-460B-B7A6-3F7893A7F6D7 Q37564201-5C5C3174-FD29-4137-8054-F2128969ACEB Q37659101-F98DDA3A-AB8C-4BB7-9A75-4888EC8E4317 Q37672081-B0ED44D2-DF80-4EAA-BF8A-A9BCFFFF10B3 Q37707387-DDBB817B-4404-4D9C-9562-D38B3FB5113D Q37831148-A9D8B9E4-1890-4478-A86E-CDD8AA92076F Q38035070-0943EBC1-E8D7-487D-9A62-5EFF78477AB1 Q38731969-CFA9EEBB-4C9C-40D7-BF08-BD88CAE7E5C6 Q39401628-43B6A6C9-1E14-4480-8CFD-A2710EB8B08D Q39912369-3BDE0878-6382-4571-98E1-ABF334D7926B Q46121027-39D27250-A42B-4519-8FCD-6796EBA596DD

P2860

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

http://www.wikidata.org/entity/Q36523502

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@ast

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@en

type

label

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@ast

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@en

prefLabel

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@ast

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@en

P1433

Q36523502-FD79180C-6BF3-4CBA-BD54-E7202E9ABEC3

P1476

Q36523502-609E4090-266A-4BD5-857D-69EF53A93CB5

P2093

Q36523502-115BD9E4-8827-430D-B0A1-E6CBEBE1C785

Q36523502-1936E4FD-35A4-4B41-B7AD-EBFED06550B2

Q36523502-D2C938AE-96FA-4F9C-98EF-0C3AA64759CD

Q36523502-E8B9F5A2-30B1-4ACE-B1CD-1D50C3FFC050

Q36523502-EF869DD0-30B5-455F-9723-31F4D3EB209C

P2860

Q36523502-00F27B54-A512-4075-B0EB-54D9F89B2E0F

Q36523502-03715A14-B67C-4F63-BE6E-FE38651C6E52

Q36523502-0831093E-2189-408E-B886-E54C7741BE6A

Q36523502-0C822C94-744B-4609-8E3F-1083C8B54009

Q36523502-0CDC5A9C-12AE-4C19-83B5-39E79EE2F2F0

Q36523502-3987C414-9A69-4688-AFEA-097D0994E935

Q36523502-55DA5E3F-A76A-4FE4-9BCC-144BD1020D16

Q36523502-665AD71E-F1F9-4D12-913F-E895178420EC

Q36523502-68E652E1-B3D0-4B27-8608-73BA2FD6BC83

Q36523502-6D168A94-36F0-4ABC-84AA-1BABE8D1460E

P304

Q36523502-E533997F-645B-4E15-8EF9-B8519B33739F

P31

Q36523502-EA48A59A-9157-4F61-BB96-EA9D3E6A9862

P356

Q36523502-EDA7E5D1-1EE6-4FEE-A60A-DB9AC7690B65

P433

Q36523502-78BABFEB-0B50-4E5E-844D-3CF828F24215

P478

Q36523502-42E56CEF-AF65-4964-A1DE-7F470AEF77A0

P577

Q36523502-07C93799-5317-451B-B580-FCA64678A261

P698

Q36523502-22EC8992-F684-4CB3-BB58-1B7FF4830491

P356

07357900600632058

P1433

Cancer Investigation

P1476

Evaluation of gefitinib for tr ...... nancies in pediatric patients.

@en

P2093

Burgess B Freeman

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

J Russell Geyer

http://www.w3.org/2001/XMLSchema#string

Najat C Daw

http://www.w3.org/2001/XMLSchema#string

Wayne L Furman

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

The ErbB signaling network: receptor heterodimerization in development and cancer

Growth factor signaling by receptor tyrosine kinases

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

The epidermal growth factor receptor and its inhibition in cancer therapy.

Development of inhibitors for protein tyrosine kinases.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

P304

310-317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900600632058

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16809160

http://www.w3.org/2001/XMLSchema#string